The histopathologic diagnosis of sarcoidosis requires the presence of noncaseating granulomas. Transbronchoscopic lung biopsy (TBLB) has been considered the procedure of choice when less invasive tissue samples are unavailable. A total of 51 consecutive patients suspected of having sarcoidosis underwent combined TBLB and flexible transbronchial needle aspirate (TBNA). In 18 of the 30 patients (60 percent) with stage I disease, the diagnosis was confirmed by TBLB and 16 (53 percent) were confirmed by TBNA. The combined use of both procedures increased the diagnostic yield to 83 percent. The remaining 21 infiltrates were present, biopsy specimens were obtained from the basal segments of the lower lobe with the greatest involvement. If no infiltrates were present, the biopsy specimens were obtained from either of the lower lobes at the discretion of the bronchoscopist. A Wang 19-gauge histologic needle (Mill-Rose Laboratories, Mentor, Ohio) was used for TBNA; the technique has been described previously.89 The TBNA biopsy specimens were obtained at the endotracheal or endobronchial location corresponding with the site of adenopathy localized by chest CT. The area of adenopathy with the largest short-axis diameter on chest CT was selected for biopsy. One to three samples were collected for both histologic and cytologic evaluation. A biopsy specimen was considered adequate if the architecture of lymph nodes was present (Fig 1) . All TBLB and TBNA were done during a single procedure. The diagnosis of sarcoidosis required the (1) presence of a noncaseating epithelioid granuloma with the absence of foreign body reaction or allergic tissue reaction, and (2) negative modified Ziehl-Neelsen carbolfuchsin and methamine silver stains as well as negative cultures for acid-fast bacilli. 
RESULTS
Of the 30 Flexible fiberoptic bronchoscopy is currently considered the diagnostic procedure of choice in sarcoidosis due to its high diagnostic yield, comfort, and lack of need for general anesthesia. The use of TBNA with flexible fiberoptic bronchoscopy for the diagnosis sarcoidosis was described by Wang et a16 in 1989. These investigators reported their findings in 20 patients (12 with stage I and 8 with stage II). Eighteen of 20 patients (90 percent) had one or more positive TBNAs. Six of these patients had their conditions diagnosed exclusively by TBNA when used in addition to TBLB and/or bronchial mucosal biopsy. The high sensitivity (90 percent) of TBNA in the diagnosis of sarcoidosis in this study was thought by the authors to be due to the high density of granulomas in lymph nodes as compared with lung tissue.
All patients in our study had a TBNA and TBLB, and we were able to compare the sensitivity of these tests directly. Our sensitivity for TBLB for stage I otherwise would have required the surgical procedure had their conditions diagnosed by TBNA, saving $22,500 which more than pays for the cost of the additional CT scan. In addition, these patients avoided the greater morbidity associated with surgery. This information suggests that CT-guided TBNA is costeffective in these patients. We believe that TBNA, in conjunction with routine TBLB, should be performed in all patients with suspected stage I and II sarcoidosis because it is cost-effective and increases the diagnostic yield.
